Eli Lilly and Co DRC (LLY)

CBOE Canada


	Symbol		Exchange		Currency
	LLY		CBOE Canada		CAD	Real-time
	LLY		NYSE		USD	Real-time
	LLY		Mexico		MXN	Delayed
	1LLY		Milan		EUR	Real-time
	LLY		Switzerland		CHF	Delayed
	LLY		Frankfurt		EUR	Delayed
	LLY		TradeGate		EUR	Delayed
	LLY		Xetra		EUR	Delayed
	LLYm		Buenos Aires		ARS	Delayed
	LILY34		B3		BRL	Delayed
	LLY		Vienna		EUR	Real-time
	LLY		Lima		USD	Delayed

Currency in CAD

Disclaimer

33.60

+0.47(+1.42%)

Closed01:29:29

Fair Value

Day's Range

33.18

33.82

52 wk Range

20.75

36.42

LLY Income Statement

Featured here, the Income Statement (earnings report) for Eli Lilly and Co DRC, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

22,319.5

24,539.8

28,318.4

28,541.4

34,124.1

Total Revenues Growth

+3.84%

+9.95%

+15.4%

+0.79%

+19.56%

Cost Of Revenues

4,721.2

5,483.3

6,973.1

6,629.8

7,082.2

Gross Profit

17,598.3

19,056.5

21,345.3

21,911.6

27,041.9

Gross Profit Growth

+4.68%

+8.29%

+12.01%

+2.65%

+23.41%

Gross Profit Margin %

78.85%

77.66%

75.38%

76.77%

79.25%

Other Operating Expenses, Total

11,598.9

11,845.7

13,072.6

13,258.3

16,254.6

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+7.54%	+2.13%	+10.36%	+1.42%	+22.6%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5,595	5,976.3	6,930.7	7,190.8	9,313.4
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	6,003.9	5,869.4	6,141.9	6,067.5	6,941.2
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

5,999.4

7,210.8

8,272.7

8,653.3

10,787.3

Operating Income Growth

-0.44%

+20.19%

+14.73%

+4.6%

+24.66%

EBIT Margin %

26.88%

29.38%

29.21%

30.32%

31.61%

Net Interest Expenses

-320.2

-326.6

-314.4

-268.8

-312.3

Net Interest Expenses Growth

-284.86%

-2%

+3.74%

+14.5%

-16.18%

Interest Expense, Total

-400.6

-359.6

-339.8

-331.6

-485.9

Interest And Investment Income

80.4

33

25.4

62.8

173.6

Other Non Operating Expenses, Total

-56.6

-195.5

51.4

-14.3

-32.7

EBT, Excl. Unusual Items

5,622.6

6,688.7

8,009.7

8,370.2

10,442.3

Gain (Loss) On Sale Of Assets

309.8

-

-

-

-

Other Unusual Items, Total

-589.2

-749.8

-2,018.1

-1,130.1

-3,822

EBT, Incl. Unusual Items

5,265.9

7,229.9

6,155.5

6,806.4

6,554.6

EBT, Incl. Unusual Items Growth

+43.09%

+37.3%

-14.86%

+10.57%

-3.7%

EBT, Incl. Unusual Items Margin

23.59%

29.46%

21.74%

23.85%

19.21%

Income Tax Expense

628

1,036.2

573.8

561.6

1,314.2

Net Income to Company

8,318.4

6,193.7

5,581.7

6,244.8

5,240.4

Minority Interest

-

-

-

-

-

Net Income

8,318.4

6,193.7

5,581.7

6,244.8

5,240.4

Net Income Growth

+157.38%

-25.54%

-9.88%

+11.88%

-16.08%

Net Income Margin %

37.27%

25.24%

19.71%

21.88%

15.36%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

4,637.9

6,193.7

5,581.7

6,244.8

5,240.4

Basic EPS - Continuing Operations

4.98

6.82

6.15

6.93

5.82

Basic EPS - Continuing Operations Growth

+62.49%

+36.99%

-9.81%

+12.53%

-15.94%

Diluted EPS - Continuing Operations

4.96

6.79

6.12

6.9

5.8

Diluted EPS - Continuing Operations Growth

+62.62%

+36.9%

-9.87%

+12.75%

-15.94%

Basic Weighted Average Shares Outstanding

931.06

907.63

906.96

901.74

900.18

Diluted Weighted Average Shares Outstanding

935.68

912.51

911.68

904.62

903.28

Dividend Per Share

2.58

2.96

3.4

3.92

4.52

Dividend Per Share Growth

+14.67%

+14.73%

+14.86%

+15.29%

+15.31%

EBITDA

7,232

8,534.7

9,820.3

10,175.8

12,314.6

EBITDA Growth

-5.28%

+18.01%

+15.06%

+3.62%

+21.02%

EBITDA Margin %